article thumbnail

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

European Pharmaceutical Review

Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. The deal is expected to close by the end of 2022, subject to approval by the relevant competition authorities. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries.

article thumbnail

Novartis knocked back again in bid to block Gilenya generics in US

pharmaphorum

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. After initially upholding the patent in January, the CAFC subsequently ruled in June that it was not valid, opening the door to low-cost competition to Novartis’ third biggest-selling product.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis takes aim at MS blockbuster Tysabri in US and Europe

pharmaphorum

The looming competition piles further pressure on Biogen, whose MS franchise is already beset by generic competition to oral therapy Tecfidera (dimethyl glutamate), while its attempt to build a market for Alzheimer’s therapy Aduhelm (aducanumab) has ended in failure.

article thumbnail

Supreme court throws Novartis a lifeline for Gilenya defense

pharmaphorum

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US. Gilenya made revenues of $2.8 Sales in the first half of this year fell 19% to $1.16

article thumbnail

Polpharma in pole position for biosimilar Tysabri in Europe

pharmaphorum

It had expected the drug would not face biosimilar competition in Europe until at least 2027. Last year, Polpharma and Sandoz won a patent challenge in Europe that resulted in revocation of a key patent on Tysabri in the EU, slashing Biogen’s protection for the brand by more than five years.

article thumbnail

Horizon Europe deal signals UK research reinvigoration

European Pharmaceutical Review

Researchers can apply for grants and bid to take part in projects with certainty that the UK will be participating as a fully associated member until the deal reaches its end in 2027.

article thumbnail

Novartis facing Gilenya generics again as Supreme Court lifts stay

pharmaphorum

Novartis’ hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have been dashed. 9,187,405, granted in 2015, which comes to an end in 2027. If they do so, Novartis has predicted it will lose $300 million in sales over the remainder of this year.